LISATA THERAPEUTICS, INC. Research and Development in Process
LISATA THERAPEUTICS, INC. (LSTA) reported Research and Development in Process of $30.39 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-30
- LISATA THERAPEUTICS, INC. research and development in process for the quarter ending 2022-12-31 was $0.00.
- LISATA THERAPEUTICS, INC. research and development in process for the quarter ending 2022-09-30 was $30.39M.
- LISATA THERAPEUTICS, INC. research and development in process for the quarter ending 2021-12-31 was $0.00.
- LISATA THERAPEUTICS, INC. research and development in process for the quarter ending 2021-09-30 was $0.00.
- LISATA THERAPEUTICS, INC. research and development in process for fiscal 2022 was $30.39M.
- LISATA THERAPEUTICS, INC. research and development in process for fiscal 2021 was $0.00.
- LISATA THERAPEUTICS, INC. research and development in process for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- LISATA THERAPEUTICS, INC. research and development in process for fiscal 2011 was $1.15M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $30.39M derived: sum of 2 quarters · filed 2023-03-30 | $30.39M 10-K · filed 2023-03-30 | |
| 2022-09-30 | $30.39M 10-Q · filed 2022-11-10 | $30.39M 10-Q · filed 2022-11-10 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 10-K · filed 2023-03-30 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $0.00 derived: sum of 2 quarters · filed 2013-03-11 | $0.00 10-K · filed 2013-03-11 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13 | $0.00 10-Q · filed 2012-11-13 | ||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-14 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $223.00K derived: sum of 2 quarters · filed 2013-03-11 | $223.00K derived: sum of 3 quarters · filed 2013-03-11 | $1.15M 10-K · filed 2013-03-11 |
| 2011-09-30 | $223.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13 | $223.00K derived: sum of 2 quarters · filed 2012-11-13 | $1.15M 10-Q · filed 2012-11-13 | |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $927.00K 10-Q · filed 2012-08-14 | ||
| 2011-03-31 | $927.00K 10-Q · filed 2012-05-11 | |||
| 2010-12-31 | $0.00 8-K · filed 2012-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |